| Ytd | -28.48% | |
| 1y | -42.35% |
| Open | 1.14 | Prev Close | 1.15 | Low | 1.09 | High | 1.16 | Mkt Cap | 211.31M |
| Vol | 0.00 | Avg Vol | 22.28M | EPS | -1.04 | P/E | -1.09 | Forward P/E | -0.55 |
| Beta | 0.63 | Short Ratio | 1.26 | Inst. Own | 35.63% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.27 | 200-d Avg | 0.92 | 1yr Est | 24.80 |
OTLK News
Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a l
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biophar
OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and up
Outlook Therapeutics (OTLK) receives both FDA and European approval for LYTENAVA, targeting wet AMD,
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet
Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analys
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and
Outlook Therapeutics said on Friday the U.S. Food and Drug Administration has approved its drug fo
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD
Outlook Therapeutics Inc. (NASDAQ:OTLK) shares are rising in Wednesday premarket trading after the c
ISELIN, N. J. , June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a bioph
Outlook Therapeutics receives a buy rating due to a recent FDA appeal victory, improving the probabi
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biophar
ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharm
Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are trading higher Tuesday after the company announc
ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharm
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.16 per share versus the Zacks Consen
ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharm
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook
ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook
U.S. stocks fall with Dow down 0.46%, S&P 500 down 0.52%, NASDAQ down 0.89%. Energy up 2.5%, com
US stocks lower on Tuesday as Dow falls over 350 points while NASDAQ and S&P 500 also decline. E
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global
